Veraxa Biotech Holding AG
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christoph Antz
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Im Neuenheimer Feld 584 Heidelberg ZH Germany 69120
- IPO Date
- Jun 9, 2026
- CIK
- 0002079109
- Website
- veraxa.com
- Similar Companies
- Business
- Veraxa Biotech Holding AG engages in the discovery, development, and advancement of next-generation antibody-based therapeutics for cancer, focusing on solid tumors and leveraging its BiTAC platform to enable conditionally activated, AND-gated strategies for increased therapeutic index; the company develops bispecific T cell engagers, antibody–drug conjugates, and related formats, with capabilities in click-chemistry conjugation, microfluidic screening, and internalization-optimized constructs across ADCs, BiTEs, and other novel formats. Veraxa operates through subsidiaries and ongoing transactions to consolidate related entities, expands its pipeline via BiTAC-enabled programs and radiopharmaceutical/conjugate platforms, and pursues partnerships for co-development and clinical progression. Headquartered in Zürich, Switzerland, Veraxa Biotech Holding AG conducts its activities through a global development footprint with clinical and research collaborations designed to advance oncology therapeutics toward the clinic and eventual commercialization. Founded in 2025, the group emerges from consolidating Veraxa Biotech AG and related entities, with a strategy to build a premier engine for discovery and development of antibody-based therapeutics and to leverage strategic alliances, potential mergers, and acquisitions to accelerate its growth trajectory in the biopharma landscape. The company's core products and services encompass therapeutic programs in ADCs, BiTEs, BiTAC-based constructs, targeted radiopharmaceuticals, and antibody conjugation technologies; development services include discovery, preclinical evaluation, analytical characterization, manufacturing process development, and translational research supporting clinical advancement; geographic operations span Europe and North America, with a focus on collaboration with biopharma partners and academic institutions to accelerate pipeline progression. Veraxa maintains a research-and-development orientation, emphasizes quality-by-design principles, and seeks to maximize patient benefit through precise tumor targeting while minimizing off-target effects. Recent corporate developments include a merger-related integration process under absorption merger terms leading to group reorganization and potential renaming to Veraxa Biotech AG, along with ongoing strategic partnerships, product pipeline expansion, and continued pursuit of co-development opportunities to broaden the commercial reach of its BiTAC-enabled therapeutics. The company is publicly tracked under ticker VRXA and maintains a strategic emphasis on solid-tumor indications, leveraging its platform across ADCs, bispecifics, and related modalities to address unmet medical needs in oncology.
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026